Antibacterial activity of contact lenses bearing surface-immobilized layers of intact liposomes loaded with levofloxacin

Journal of Pharmaceutical Sciences

Volumn 96, Issue 9, 2007, Pages 2350-2363

  Danion, Anne ^a,b   Arsenault, Isabelle ^a,b   Vermette, Patrick ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

Author keywords

Biomaterials; Coating; Contact lens; Controlled release; Immobilized layers of intact liposomes; In vitro models; Kinetic of antibiotic release; Staphylococcus aureus; Targeted drug delivery

Indexed keywords

AGAR; LEVOFLOXACIN; LIPOSOME;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CHEMICAL MODIFICATION; CONTACT LENS; DRUG MECHANISM; DRUG RELEASE; EYE INFECTION; FLUORESCENCE ANALYSIS; GROWTH INHIBITION; IMMOBILIZED BIOMASS; KERATITIS; KINETICS; PREVENTION; STAPHYLOCOCCUS AUREUS; TREATMENT INDICATION;

EID: 34748918564     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20871     Document Type: Article

References (49)

1. Maberley D. 2004. The cost of blindness symposium. Toronto, Jan 31-Feb 1.
2. McCarty CA, Mukesh BN, Fu CL, Taylor HR. 1999. The epidemiology of cataract in Australia. Am J Ophthalmol 128:446-465.
3. World Health Organization Report. 1997.
4. Singh K, Bautista RD. editors. 1999. International ophthalmology clinics, Vol. 39. Philadelphia: Lippincott Williams & Wilkins.
5. Smolin G. editor. 1998. International ophthalmology clinics, Vol. 38. Philadelphia: Lippincott Williams & Wilkins.
6. Arffa RC. 1997. Viral diseases. In: Arffa RC, Grayson M, editors. Grayson's diseases of the cornea, 4th ed. St-Louis: Mosby. pp 283-338.
7. Ogawa GS, Hyndiuk RA. 1994. Bacterial keratitis and conjunctivitis - clinical disease. In: Smolin G, Thoft RA, editors. The cornea: Scientific foundations and clinical practice. 3rd ed. Boston: Little, Brown and Company. pp 125-167.
8. Garg P, Bansal AK, Sharma S, Vemuganti GK. 2001. Bilateral infectious keratitis after laser in situ keratomileusis: A case report and review of the literature. Ophthalmology 108:121-125.
9. Liesegang TJ. 1988. Bacterial and fungal keratitis. In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, editors. The cornea. New York: Churchill Livingstone. pp 217-270.
10. Alexandrakis G, Alfonso EC, Miller D. 2000. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 107:1497-1502.
11. Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. 2003. Bacterial keratitis: Predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol 87:834-838.
12. Callegan MC, O'Callaghan RJ, Hill JM. 1994. Pharmacokinetic considerations in the treatment of bacterial keratitis. Clin Pharmacokinet 27:129-149.
13. Holland SP, Pulido JS, Shires TK, Costerton JW. 1993. Pseudomonas aeruginosa ocular infections. In: Fick RB, editor. Pseudomonas aeruginosa: The opportunist. Boca Raton: CRC Press Inc. pp 160-176.
14. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. 2001. Bacterial keratitis: A prospective clinical and microbiological study. Br J Ophthalmol 85:842-847.
15. Smith A, Pennefather PM, Kaye SB, Hart CA. 2001. Fluoroquinolones - place in ocular therapy. Drugs 61:747-761.
16. Gangopadhyay N, Daniell M, Weih L, Taylor HR. 2000. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol 84:378-384.
17. Cutarelli PE, Lass JH, Lazarus HM, Putman SC, Jacobs R. 1991. Topical fluoroquinolones: Antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res 10:557-563.
18. Mallari PL, McCarty DJ, Daniell M, Taylor HR. 2001. Increased incidence of corneal perforation following topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol 131:131-133.
19. Goldstein MH, Kowalski RP, Gordon YJ. 1999. Emerging fluoroquinolone resistance in bacterial queratitis. A five-year review. Ophthalmology 106:1313-1318.
20. Kowalski RP, Pandya AN, Karenchak LM. 2001. An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology 108:1826-1829.
21. Chalita MR, Hofling-Lima AL, Paranhos A, Jr., Schor P, Belfort R, Jr. 2004. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 137:43-51.
22. Marangon FB, Miller D, Muallem MS. 2004. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 137:453-458.
23. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. 1998. Ophthalmic drug delivery systems. Prog Retin Eye Res 17:33-58.
24. Lang JC. 1995. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv 16:39-43.
25. Segal M. 1991. Patches, pumps and timed release. FDA Consumer Magazine. October 1991. Available at http://www.fda.gov/bbs/topics/CONSUMER/CON00112.html.
26. Nagarsenker MS, Londhe VY, Nadkarni GD. 1990. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm 190:63-71.
27. Malmsten M, editor. 2002. Surfactants and polymers in drug delivery. New York: Marcel Dekker.
28. Loftsson T, Stefansso E. 2002. Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 80:144-150.
29. Smollin G, Friedlaender MH. editors. 1991. International ophthalmology clinics, Vol. 31. Philadelphia: Lippincott Williams & Wilkins.
30. Guo LSS, Redemann CT, Radhakrishnan R, Yau-Young A. 1989. Liposomes with enhanced retention on mucosal tissue. US Patent No. 4839175.
31. Reidy JJ, Gebhardt BM, Kaufman HE. 1990. The collagen shield: A new vehicle for delivery of cyclosporin A to the eye. Cornea 9:196-199.
32. Phinney RB, Schwartz SD, Lee DA, Mondino BJ. 1988. Collagen-shield delivery of gentamicin and vancomycin. Arch Ophthalmol 106:1599-1604.
33. Peterson RC, Wolffsohn JS, Nick J, Winterton L, Lally J. 2006. Clinical performance of daily disposable soft contact lenses using sustained release technology. Contact Lens & Anterior Eye 29(3):127-134.
34. Hiratani H, Mizutani Y, Alvarez-Lorenzo C. 2005. Controlling drug release from imprinted hydrogels by modifying the characteristics of the imprinted cavities. Macromol Biosci 5:728-733.
35. Lesher GA, Gunderson GG. 1993. Continuous drug delivery through the use of disposable contact lenses. Optom Vis Sci 70:1012-1018.
36. Barber RF, Shek PN. 1990. Tear-induced release of liposome-entrapped agents. Int J Pharm 60:219-227.
37. Popescu MC, Weiner AL, Carpenter-Green SS. 1985. Liposome-gel compositions. International Patent No. WO85/03640.
38. Gulsen D, Li CC, Chauhan A. 2005. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Current Eye Res 30:1071-1080.
39. Chauhan A, Gulsen D. 2004. Ophthalmic drug delivery system. U.S. Patent No. 0241207.
40. Vermette P, Meagher L, Gagnon E, Griesser HJ, Doillon CJ. 2002. Immobilized liposomes layers for drug delivery applications: Inhibition of angiogenesis. J Control Release 80:179-185.
41. Vermette P, Griesser HJ, Kambouris P, Meagher L. 2004. Characterization of surface-immobilized layers of intact liposomes. Biomacromolecules 5:1496-1502.
42. Danion A, Brochu H, Martin Y, Vermette P. 2006. Fabrication and characterization of contact lenses bearing surface-immobilized layers of intact liposomes. J Biomed Mater Res, Part A, in press.
43. North DS, Fish N, Redington JJ. 1998. Levofloxacin, a second-generation fluoroquinolone. Pharmacotherapy 18:915-935.
44. Callegan MC, Engelberg M, Parke DW, Jett BD, Gilmore MS. 2002. Bacterial endophthalmitis: Epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev 15:111-124.
45. Hope M, Bally M, Mayer L, Janoff A, Cullis P. 1986. Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 40:89-107.
46. Vermette P, Gengenbach T, Divisekera U, Kambouris PA, Griesser HJ, Meagher L. 2003. Immobilization and surface characterization of NeutrAvidin biotin-binding protein on different hydrogel interlayers. J Colloid Interface Sci 259:13-26.
47. National Committee for Clinical Laboratory Standards. 1997. Performance Standards for antimicrobial disk susceptibility tests - 6th ed.: Approved Standard M2-A6. NCCLS, Wayne, PA.
48. Noviello S, Ianniello F, Leone S, Esposito S. 2003. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother 52:869-872.
49. Oguz H, Ozbilge H, Oguz E, Gurkan T. 2005. Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. Current Eye Res 30:155-161.